Vaxart Inc
NASDAQ:VXRT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
OVB Holding AG
XETRA:O4B
|
DE |
Vaxart Inc
Other Liabilities
Vaxart Inc
Other Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Vaxart Inc
NASDAQ:VXRT
|
Other Liabilities
$8.8m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
11%
|
CAGR 10-Years
46%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Liabilities
$32.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
3%
|
CAGR 10-Years
24%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Liabilities
$2.1B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Liabilities
$5.1B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
4%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Liabilities
$3B
|
CAGR 3-Years
41%
|
CAGR 5-Years
36%
|
CAGR 10-Years
51%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Liabilities
$2.2B
|
CAGR 3-Years
47%
|
CAGR 5-Years
24%
|
CAGR 10-Years
11%
|
|
Vaxart Inc
Glance View
Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. The company is headquartered in South San Francisco, California and currently employs 110 full-time employees. Its programs include tablet vaccines designed to protect against coronavirus, norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV). The Company’s product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. The firm is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus.
See Also
What is Vaxart Inc's Other Liabilities?
Other Liabilities
8.8m
USD
Based on the financial report for Dec 31, 2025, Vaxart Inc's Other Liabilities amounts to 8.8m USD.
What is Vaxart Inc's Other Liabilities growth rate?
Other Liabilities CAGR 10Y
46%
Over the last year, the Other Liabilities growth was -41%. The average annual Other Liabilities growth rates for Vaxart Inc have been -23% over the past three years , 11% over the past five years , and 46% over the past ten years .
